Jefferies Downgrades Harmony Biosciences to Hold, Announces $57 Price Target

Jefferies analyst Chris Howerton downgrades Harmony Biosciences (NASDAQ:HRMY) from Buy to Hold and announces $57 price target.

Jefferies analyst Chris Howerton downgrades Harmony Biosciences (NASDAQ:HRMY) from Buy to Hold and announces $57 price target.

Total
0
Shares
Related Posts